MFDS Approves iGene's COVID-19 Vaccine Phase 1 and 2a Clinical Trial Plan

11 COVID-19 Vaccines Currently in Clinical Trials in Korea

[Asia Economy Reporter Kim Ji-hee] The Ministry of Food and Drug Safety announced on the 31st that it has approved the clinical phase 1 and 2a trial plans for the COVID-19 vaccine ‘EG-COVID’ developed by IGEN.

With simultaneous approval for phases 1 and 2a, IGEN plans to confirm safety in phase 1 and then sequentially proceed with phase 2a.

EG-COVID is a messenger ribonucleic acid (mRNA) vaccine containing the surface antigen protein information of the COVID-19 virus. Liposomes (tiny spherical double membranes made of phospholipids and cholesterol) were used as the delivery material for mRNA into cells. This vaccine injects the gene carrying the COVID-19 virus antigen information in the form of mRNA, synthesizes antigen proteins inside the body, and these antigen proteins stimulate immune cells to induce the production of neutralizing antibodies that can neutralize the virus.

With this approval, the total number of pharmaceuticals conducting clinical trials related to COVID-19 in Korea has increased to 24, including 11 vaccines and 13 therapeutics (12 ingredients).

This content was produced with the assistance of AI translation services.